scholarly journals Off-Label Drug Use in Ocular Behçet's Disease in Turkey

2021 ◽  
Vol 28 (2) ◽  
pp. 243-248
Author(s):  
HANİFE RAHMANLAR ◽  
Mehmet Murat uzel ◽  
Mehmet Çıtırık ◽  
Ali Alkan ◽  
Hakkı Gürsöz
2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A13.3-A14
Author(s):  
MH García Lagunar ◽  
M Gutiérrez Cívicos ◽  
R Guerrero Bautista ◽  
E Ferris Villanueva ◽  
A García Márquez ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Daniel Sánchez-Cano ◽  
José Luis Callejas-Rubio ◽  
Ricardo Ruiz-Villaverde ◽  
Raquel Ríos-Fernández ◽  
Norberto Ortego-Centeno

Tumoral necrosis factorαplays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet’s disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series.


2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A13.1-A13
Author(s):  
MH García Lagunar ◽  
M Gutiérrez Cívicos ◽  
R Guerrero Bautista ◽  
E Ferris Villanueva ◽  
A García Márquez ◽  
...  

2021 ◽  
pp. ejhpharm-2021-002785
Author(s):  
Mehmet Citirik ◽  
Cemile Ucgul Atilgan ◽  
Hanife Rahmanlar ◽  
Ali Alkan ◽  
Hakki Gursoz

1991 ◽  
Vol 66 (03) ◽  
pp. 292-294 ◽  
Author(s):  
K K Hampton ◽  
M A Chamberlain ◽  
D K Menon ◽  
J A Davies

SummaryCoagulation and fibrinolytic activities were studied in 18 subjects with Behçet's disease and compared with results from 14 matched control patients suffering from sero-negative arthritis. Significantly higher plasma concentrations (median and range) were found in Behçet's patients for the following variables: fibrinogen 3.7 (1.7-6.9) vs 3.0 (2.0-5.1) g/1, p <0.05; von Willebrand factor antigen, 115 (72-344) vs 74 (60-119)%, p <0.002; plasminogen activator activity (106/ECLT2) 219 (94-329) vs 137 (78-197) units, p <0.002; tissue plasminogen activator inhibitor (t-PA-I) activity, 9.1 (5.5-19.3) vs 5.1 (1.8-12.0) IU/ml, p <0.002; and PAI-1 antigen, 13.9 (4.5-20.9) vs 6.4 (2.4-11.1) ng/ml, p <0.002. Protein C antigen was significantly lower: 97 (70-183) vs 126 (96-220)%, p <0.02. No differences were observed in antithrombin III activity or antigen, factor VIII coagulant activity, fibrinopeptides A and Bβ15-42, plasminogen, α-2-antiplasmin, functional and immunological tissue-plasminogen activator, thrombin-antithrombin complexes and D-dimer. Levels of tissue plasminogen activator inhibitor (activity and antigen) correlated with disease activity while fibrinogen and von Willebrand factor concentrations did not. Seven of the 18 subjects with Behçet's disease had suffered thrombotic events but it was not possible to distinguish these from the 11 patients without thrombosis using the assays performed. The results suggest the abnormal fibrinolytic activity in Behçet's disease is due to increased inhibition of tissue plasminogen activator. No abnormality of coagulation or fibrinolytic activity specific to Behçet's disease was detected.


1996 ◽  
Vol 75 (06) ◽  
pp. 974-975 ◽  
Author(s):  
İbrahim C Haznedaroğlu ◽  
Oktay Özdemir ◽  
Osman Özcebe ◽  
Semra V Dündar ◽  
Şerafettin Kirazli

1993 ◽  
Vol 29 (1) ◽  
pp. 62 ◽  
Author(s):  
Kyung Hwan Lee ◽  
Jae Hyung Park ◽  
Joon Ku Han ◽  
Hyun Ae Park ◽  
Jin Wook Chung ◽  
...  

2018 ◽  
Author(s):  
Ferreira Paulo Carvalho ◽  
Bruno Maia ◽  
Antonio Marinho ◽  
Ana Veloso ◽  
Ivo Cunha ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document